Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

The focus of the Merks group is to answer key clinical questions in pediatric sarcoma treatment with the aim to improve cure and quality of life. As Chair of the European pediatric Soft tissue sarcoma Study Group (EpSSG) and Vice-Chair of the Executive Board of the EuroEwing Consortium (EEC) Merks’ aim is to coordinate, design and implement international prospective clinical trials, including translational research, focused on sarcoma across the pediatric and young adult age range. Research in pediatric sarcoma pre-eminently is a multidisciplinary collaboration including a diversity of basic, translational and clinical research partners.
  • Genetic evaluation of five patients with ROHHAD-NET using whole genome sequencing and optical genome mapping

    • dec. 2025
    • N., van Engelen, et al
    • Orphanet Journal of Rare Diseases
  • Small round cell sarcoma tumoroid biobank reveals CIC::DUX4 sarcoma vulnerability to MCL-1 inhibition

    • dec. 2025
    • Femke C.A.S., Ringnalda, et al
    • Nature communications
  • Dental Adverse Effects Following Multimodality Treatment for Head and Neck Rhabdomyosarcoma

    • nov. 2025
    • Koen B., Krommenhoek, et al
    • Pediatric Blood and Cancer
  • Single site metastatic rhabdomyosarcoma

    • okt. 2025
    • Federico, Mercolini, et al
    • European Journal of Cancer
  • Surgical Lymph Node Staging in Extremity Rhabdomyosarcoma

    • okt. 2025
    • Sheila, Terwisscha van Scheltinga, et al
    • Annals of surgical oncology
View all publications